Postmastectomy Breast Reconstruction is Safe in Patients on Chronic Anticoagulation.

Archives of plastic surgery 2022 Vol.49(3) p. 346-351

Yan M, Kuruoglu D, Boughey JC, Manrique OJ, Tran NV, Harless CA, Martinez-Jorge J, Nguyen MT

관련 도메인

Abstract

 Postmastectomy breast reconstruction (PMR) increases patient satisfaction, quality of life, and psychosocial well-being. There is scarce data regarding the safety of PMR in chronic anticoagulated patients. Perioperative complications can reduce patient satisfaction; therefore, it is important to elucidate the safety of PMR in these patients.  A retrospective case-control study of patients who underwent PMR with implants and were on chronic anticoagulation was performed at our institution. Inclusion criteria were women ≥ 18 years old. Exclusion criteria included autologous reconstructions, lumpectomy, and oncoplastic procedures. Two controls for every one patient on anticoagulation were matched by age, body mass index, radiotherapy, smoking history, type of reconstruction, time of reconstruction, and laterality.  From 2009 to 2020, 37 breasts (20 patients) underwent PMR with implant-based reconstruction and were on chronic anticoagulation. A total of 74 breasts (40 patients) who had similar demographic characteristics to the cases were defined as the control group. Mean age for the case group was 53.6 years (standard deviation [SD] = 16.1), mean body mass index was 28.6 kg/m (SD = 5.1), and 2.7% of breasts had radiotherapy before reconstruction and 5.4% after reconstruction. Nine patients were on long-term warfarin, six on apixaban, three on rivaroxaban, one on low-molecular-weight heparin, and one on dabigatran. The indications for anticoagulation were prior thromboembolic events in 50%. Anticoagulated patients had a higher risk of capsular contracture (10.8% vs. 0%,  = 0.005). There were no differences regarding incidence of hematoma (2.7% vs. 1.4%,  = 0.63), thromboembolism (5% vs. 0%,  = 0.16), reconstructive-related complications, or length of hospitalization (1.6 days [SD = 24.2] vs. 1.4 days [SD = 24.2],  = 0.85).  Postmastectomy implant-based breast reconstruction can be safely performed in patients on chronic anticoagulation with appropriate perioperative management of anticoagulation. This information can be useful for preoperative counseling on these patients.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
해부 breast 유방 dict 3
해부 breasts scispacy 1
합병증 hematoma 혈종 dict 1
합병증 capsular contracture 피막구축 dict 1
약물 PMR → Postmastectomy breast reconstruction scispacy 1
약물 warfarin C0043031
warfarin
scispacy 1
약물 apixaban C1831808
apixaban
scispacy 1
약물 rivaroxaban C1739768
rivaroxaban
scispacy 1
약물 dabigatran C2348066
dabigatran
scispacy 1
약물 low-molecular-weight heparin scispacy 1
약물 [SD scispacy 1
질환 breasts C0006141
Breast
scispacy 1
질환 thromboembolic C0333214
thromboembolic
scispacy 1
질환 thromboembolism C0040038
Thromboembolism
scispacy 1
질환 PMR → Postmastectomy breast reconstruction scispacy 1
질환 lumpectomy scispacy 1
기타 Patients scispacy 1
기타 patient scispacy 1
기타 women scispacy 1

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문